Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker?

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9241-9246

  Nigam, Jaya ^a   Chandra, Abhijit ^a   Kazmi, Hasan Raza ^a   Parmar, Devendra ^b   Singh, Devendra ^a   Gupta, Vishal ^a   M, Noushif ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Gallbladder cancer; Gallstone; Prognosis; Survivin

Indexed keywords

BETA ACTIN; LIOTHYRONINE; MESSENGER RNA; SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHOLELITHIASIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GALLBLADDER CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; BLOOD; DIFFERENTIAL DIAGNOSIS; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84908182197     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2200-x     Document Type: Article

References (33)

1. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64.
2. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167–76.
3. Rifatbegovic Z, Mesic D, Ljuca F, Zildzic M, Morankic M. Incidence and surgical treatment of cancer in gallbladder. Med Arh. 2007;61(1):30–3.
4. Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinoma of the gallbladder. Results of the French surgical association survey. Ann Surg. 1994;219(3):275–80.
5. Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, et al. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg. 2004;8(2):183–90.
6. Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J Surg Oncol. 2006;93(8):665–9.
7. Levy AD, Murakata LA, Rohrmann CA. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics. 2001;21(2):295–314.
8. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580–4.
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.
10. Bafford R, Sui XX, Wang G, Conte M. Angiotensin II and tumor necrosis factor-alpha upregulate survivin and Kruppel-like factor 5 in smooth muscle cells: potential relevance to vein graft hyperplasia. Surgery. 2006;140(2):289–96.
11. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70.
12. Guney N, Soydine HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum and urine survivin levels in breast cancer. Med Oncol. 2006;23(3):335–9.
13. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.
14. Wen SF, Mahavni V, Quijano E, Shinoda J, Grace M, Musco-Hobkinson ML, et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003;10(3):224–38.
15. Altieri DC. Survivin in apoptosis and cell cycle regulation in cancer. Prog Cell Cycle Res. 2003;5:447–52.
16. Kennedy TC, Hirsch FR. Using molecular markers in sputum for the early detection of lung cancer: a review. Lung Cancer. 2004;45:21–7.
17. Hoffmann AC, Warnecke-Eberz U, Luebke T, Prenzel K, Metzger R, Heitmann M, et al. Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol. 2007;95(1):51–4.
18. Dong DQ, Yang YH, Xue DY, Feng XJ. Expression of survivin mRNA of sputum and pleural effusions in human lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31(6):848–52.
19. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285(3):324–8.
20. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, et al. Detection of cell BIRC5 mRNA in effusion and its potential diagnostic value for differentiating malignant and benign effusion. Int J Cancer. 2009;125(8):1921–5.
21. Altznauer F, Martinelli S, Yousefi S, Thurig C, Schmid I, Conway EM, et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med. 2004;199(10):1343–54.
22. Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, Czarnywojtek A, et al. Survivin—prognostic tumor biomarker in human neoplasms—review. Ginekol Pol. 2012;83(7):537–40.
23. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Immunohistochem Mol Morphol. 2004;12(4):296–304.
24. Kim H, Shiraki K, Park S. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res. 2002;22(2A):805–8.
25. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin and prognosis of neuroblastoma. Lancet. 1998;351(9106):882–3.
26. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: reexpression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol. 1999;17(7):2100–4.
27. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46(5):645–50.
28. Song J, Su H, Zhou YY, Guo LL. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013;34(4):2053–62.
29. Lv S, Turlova E, Zhao S, Kang H, Han M, Sun HS. Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumour Biol. 2014;35(2):1565–74.
30. Wang ZN, Xu HM, Jiang L, Zhou X, Lu C, Zhang X. Expression of survivin mRNA in peritoneal lavage fluid from patients with gastric carcinoma. Chin Med J (Engl). 2004;117(8):1210–7.
31. Yie SM, Lou B, Ye SR, He X, Cao M, Xie K, et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer. 2009;63(2):284–90.
32. Kapellos G, Polonifi K, Farmakis D, Spartalis E, Tomos P, Aessopos A, et al. Overexpression of survivin levels in circulation and tissue samples of lung cancer patients. Anticancer Res. 2013;33(8):3475–80.
33. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17(4):597–604.